Jump to content

Ralph DeBerardinis

Add links
From Wikipedia, the free encyclopedia
Ralph J. DeBerardinis
AwardsPaul Marks Prize for Cancer Research; Edith and Peter O'Donnell Award in Medicine
Scientific career
FieldsCancer; Metabolism
Thesis[ProQuest 304449466 Retrotransposition and evolution of L1 sequences in mammalian genomes] (1998)
Doctoral advisorHaig H. Kazazian Jr
Other academic advisorsCraig Thompson
Websitehttps://cri.utsw.edu/scientists/ralph-deberardinis-laboratory/

Ralph J. DeBerardinis is an American physician-scientist, the chief of the Division of Pediatric Genetics and Metabolism at the Children’s Medical Center Research Institute at UT Southwestern and a professor at the University of Texas Southwestern Medical Center. DeBerardinis became a Howard Hughes Medical Institute Investigator in 2018.[1] DeBerardinis was elected to the National Academy of Medicine in 2020.[2] DeBerardinis is known for his contributions to research on cancer and pediatric inborn errors of metabolism.

Biography

[edit]

DeBerardinis was born and raised in the Philadelphia area.[3] DeBerardinis received a Bachelor of Science (BS) degree from St. Joseph’s University and M.D. and Ph.D. degrees from the University of Pennsylvania.[4][5] DeBerardinis completed his Ph.D. in the laboratory of Haig H. Kazazian Jr.[6] DeBerardinis was an inaugural trainee of the combined Pediatrics/Genetics Residency program at The Children’s Hospital of Philadelphia (CHOP).[4] DeBerardinis has achieved board certifications in clinical biochemical genetics, medical genetics, and pediatrics.[5] DeBerardinis performed his postdoctoral research in the laboratory of Craig Thompson while he was at the Penn Cancer Center.[7] After completing his postdoctoral work, DeBerardinis opened his own research laboratory in 2008 at University of Texas Southwestern Medical Center.[4][3]

DeBerardinis has been on the Scientific Advisory Boards of several companies, including Agios Pharmaceuticals, Peloton Therapeutics, and Vida Ventures.[3][8] As of April 2022, DeBerardinis has authored over 350 publications and has an h-index of 94.[9]

Scientific contributions

[edit]

DeBerardinis is well known for his use of isotope-tracing metabolomics to identify how tumors utilize different nutrients. Using genomics and metabolomics approaches, DeBerardinis also has worked to identify novel mutations that affect the activity of metabolic enzymes.[1][10]

Selected awards and honors

[edit]

Selected publications

[edit]

References

[edit]
  1. ^ a b c "Ralph J. DeBerardinis". HHMI. Retrieved 2022-04-24.
  2. ^ a b "National Academy of Medicine Elects 100 New Members". National Academy of Medicine. 2020-10-19. Retrieved 2022-04-24.
  3. ^ a b c "Ralph DeBerardinis - Scientific Advisory Board Member at Vida Ventures". THE ORG. Retrieved 2022-04-24.
  4. ^ a b c "Ralph DeBerardinis Laboratory | Children's Research Institute | Dallas TX". Children's Research Institute | Dallas Texas. Retrieved 2022-04-24.
  5. ^ a b children's health. "Biography: Ralph John DeBerardinis, MD". Retrieved 2022-04-23.
  6. ^ DeBerardinis, Ralph John (1998). Retrotransposition and evolution of L1 sequences in mammalian genomes (Thesis). OCLC 187477554. ProQuest 304449466.[page needed][non-primary source needed]
  7. ^ a b "Meet Ralph DeBerardinis, a Recipient of the Paul Marks Prize for Cancer Research | Memorial Sloan Kettering Cancer Center". www.mskcc.org. 28 February 2022. Retrieved 2022-04-24.
  8. ^ "Leadership". Agios. Retrieved 2022-04-24.
  9. ^ "Ralph DeBerardinis". scholar.google.com. Retrieved 2022-04-24.
  10. ^ "Ralph DeBerardinis, MD, PhD". HHMI. Retrieved 2022-04-24.
  11. ^ "2017 Outstanding Investigator Award (OIA) Recipients - National Cancer Institute". www.cancer.gov. 2018-10-15. Retrieved 2022-04-24.
  12. ^ "2019 O'Donnell Awards Recipients - TAMEST". TAMEST The Academy of Medicine, Engineering and Science of Texas. Retrieved 2022-04-24.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ralph_DeBerardinis&oldid=1217700244"